1. Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction.
- Author
-
Kim JH, Jung K, Lee C, Song D, Kim K, Yoo HC, Park SJ, Kang JS, Lee KR, Kim S, Han JM, and Han G
- Subjects
- Cell Line, Cell Survival drug effects, Dose-Response Relationship, Drug, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors chemistry, Humans, Leucine-tRNA Ligase metabolism, Mechanistic Target of Rapamycin Complex 1 metabolism, Molecular Structure, Monomeric GTP-Binding Proteins metabolism, Pyrazolones chemical synthesis, Pyrazolones chemistry, Structure-Activity Relationship, Enzyme Inhibitors pharmacology, Leucine-tRNA Ligase antagonists & inhibitors, Mechanistic Target of Rapamycin Complex 1 antagonists & inhibitors, Monomeric GTP-Binding Proteins antagonists & inhibitors, Pyrazolones pharmacology
- Abstract
The enzyme leucyl-tRNA synthetase (LRS) and the amino acid leucine regulate the mechanistic target of rapamycin (mTOR) signaling pathway. Leucine-dependent mTORC1 activation depends on GTPase activating protein events mediated by LRS. In a prior study, compound BC-LI-0186 was discovered and shown to interfere with the mTORC1 signaling pathway by inhibiting the LRS-RagD interaction. However, BC-LI-0186 exhibited poor solubility and was metabolized by human liver microsomes. In this study, in silico physicochemical properties and metabolite analysis of BC-LI-0186 are used to investigate the addition of functional groups to improve solubility and microsomal stability. In vitro experiments demonstrated that 7b and 8a had improved chemical properties while still maintaining inhibitory activity against mTORC1. The results suggest a new strategy for the discovery of novel drug candidates and the treatment of diverse mTORC1-related diseases., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF